BRPI1004572A2 - "fusões genéticas recorrentes em câncer - Google Patents
"fusões genéticas recorrentes em câncerInfo
- Publication number
- BRPI1004572A2 BRPI1004572A2 BRPI1004572A BRPI1004572A BRPI1004572A2 BR PI1004572 A2 BRPI1004572 A2 BR PI1004572A2 BR PI1004572 A BRPI1004572 A BR PI1004572A BR PI1004572 A BRPI1004572 A BR PI1004572A BR PI1004572 A2 BRPI1004572 A2 BR PI1004572A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- genetic fusions
- recurrent genetic
- recurrent
- fusions
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 230000000306 recurrent effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14359809P | 2009-01-09 | 2009-01-09 | |
US18777609P | 2009-06-17 | 2009-06-17 | |
PCT/US2010/020501 WO2010081001A2 (en) | 2009-01-09 | 2010-01-08 | Recurrent gene fusions in cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI1004572A2 true BRPI1004572A2 (pt) | 2016-04-05 |
Family
ID=42317163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1004572A BRPI1004572A2 (pt) | 2009-01-09 | 2010-01-08 | "fusões genéticas recorrentes em câncer |
Country Status (10)
Country | Link |
---|---|
US (1) | US20120015839A1 (pt) |
EP (1) | EP2382328A2 (pt) |
JP (1) | JP2012514475A (pt) |
KR (1) | KR20110111474A (pt) |
CN (1) | CN102639709A (pt) |
AU (1) | AU2010203517B2 (pt) |
BR (1) | BRPI1004572A2 (pt) |
CA (1) | CA2749113A1 (pt) |
IL (1) | IL213916A0 (pt) |
WO (1) | WO2010081001A2 (pt) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008058018A2 (en) | 2006-11-02 | 2008-05-15 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
AU2009253675A1 (en) | 2008-05-28 | 2009-12-03 | Genomedx Biosciences, Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
CN102439174B (zh) * | 2009-02-19 | 2015-02-04 | 康奈尔大学 | 基于检测slc45a3-elk4融合转录子的用于诊断前列腺癌的组合物和方法 |
US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
KR101415736B1 (ko) | 2011-05-25 | 2014-07-04 | 한국생명공학연구원 | 신규한 인간 융합 유전자 또는 이의 융합 유전자 전사 변이체, 및 이의 용도 |
WO2013089882A2 (en) * | 2011-09-27 | 2013-06-20 | The Regents Of The University Of Michigan | Recurrent gene fusions in breast cancer |
CA2858581A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
CN102758006B (zh) * | 2012-04-25 | 2014-03-12 | 武汉艾迪康医学检验所有限公司 | 用于检测白血病BCR/ABL(b3a2,b2a2)融合基因相对表达量的试剂盒 |
US11035005B2 (en) | 2012-08-16 | 2021-06-15 | Decipher Biosciences, Inc. | Cancer diagnostics using biomarkers |
CA2905410A1 (en) | 2013-03-15 | 2014-09-25 | Abbott Molecular Inc. | Systems and methods for detection of genomic copy number changes |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
EP3027654B1 (en) | 2013-07-30 | 2019-09-25 | Blueprint Medicines Corporation | Pik3c2g fusions |
JP6493681B2 (ja) * | 2013-08-20 | 2019-04-03 | 学校法人関西医科大学 | 肺がんで見出された新規融合遺伝子 |
US20160340742A1 (en) * | 2014-02-04 | 2016-11-24 | Mayo Foundation For Medical Education And Research | Method of Identifying Tyrosine Kinase Receptor Rearrangements in Patients |
US20170044622A1 (en) | 2014-04-18 | 2017-02-16 | Blueprint Medicines Corporation | Pik3ca fusions |
US10246750B2 (en) | 2014-06-10 | 2019-04-02 | Blueprint Medicines Corporation | Method for detection of a TECR:PKN1 or an ANXA4:PKN1 gene fusion |
US9994912B2 (en) | 2014-07-03 | 2018-06-12 | Abbott Molecular Inc. | Materials and methods for assessing progression of prostate cancer |
CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
JP2018506720A (ja) * | 2015-02-13 | 2018-03-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ccpおよび抗pik3cdを測定することによる関節リウマの査定方法 |
GB2557818A (en) * | 2015-09-25 | 2018-06-27 | Veracyte Inc | Methods and compositions that utilize transciptome sequencing data in machine learning-based classification |
EP3445875B1 (en) | 2016-04-22 | 2023-01-18 | President and Fellows of Harvard College | Methods for attaching cellular constituents to a matrix |
EP3504348B1 (en) | 2016-08-24 | 2022-12-14 | Decipher Biosciences, Inc. | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
US11208697B2 (en) | 2017-01-20 | 2021-12-28 | Decipher Biosciences, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
EP3593140A4 (en) | 2017-03-09 | 2021-01-06 | Decipher Biosciences, Inc. | SUBTYPING PROSTATE CANCER TO PREDICT RESPONSE TO HORMONE THERAPY |
AU2018266733A1 (en) | 2017-05-12 | 2020-01-16 | Veracyte, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
CN112770776A (zh) | 2018-07-30 | 2021-05-07 | 瑞德库尔有限责任公司 | 用于样品处理或分析的方法和系统 |
CN109117796B (zh) * | 2018-08-17 | 2021-01-08 | 广州市锐博生物科技有限公司 | 碱基识别方法及装置、生成彩色图像的方法及系统 |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
CN110592213A (zh) * | 2019-09-02 | 2019-12-20 | 深圳市新合生物医疗科技有限公司 | 预测新抗原负荷和检测基因组突变的基因panel |
WO2022009052A2 (en) * | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
CA3201624A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors |
CN113215162B (zh) * | 2021-06-02 | 2023-08-22 | 山西医科大学 | 降低铝致Aβ1-42表达水平的干扰RNA及其应用 |
AU2022339821A1 (en) * | 2021-08-31 | 2024-03-07 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4109496A (en) | 1977-12-20 | 1978-08-29 | Norris Industries | Trapped key mechanism |
US4323546A (en) | 1978-05-22 | 1982-04-06 | Nuc Med Inc. | Method and composition for cancer detection in humans |
US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
EP0232967B1 (en) | 1986-01-10 | 1993-04-28 | Amoco Corporation | Competitive homogeneous assay |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5283174A (en) | 1987-09-21 | 1994-02-01 | Gen-Probe, Incorporated | Homogenous protection assay |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US4968103A (en) | 1988-07-22 | 1990-11-06 | Photofinish Cosmetics Inc. | Method of making a brush |
US5225326A (en) | 1988-08-31 | 1993-07-06 | Research Development Foundation | One step in situ hybridization assay |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8901778D0 (en) | 1989-01-27 | 1989-03-15 | Univ Court Of The University O | Manipulatory technique |
ATE141956T1 (de) | 1989-07-11 | 1996-09-15 | Gen Probe Inc | Verfahren zur vervielfältigung von nukleinsäuresequenzen |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5270184A (en) | 1991-11-19 | 1993-12-14 | Becton, Dickinson And Company | Nucleic acid target generation |
US5545524A (en) | 1991-12-04 | 1996-08-13 | The Regents Of The University Of Michigan | Compositions and methods for chromosome region-specific probes |
DE69326967T2 (de) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phasenmodulationsenergieübertragungsfluoroimmunassay |
DE69333969T2 (de) | 1992-10-30 | 2006-09-14 | The General Hospital Corp., Boston | Wechselwirkendes Fallensystem zur Isolierung von Proteinen |
GB9223084D0 (en) | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
RU2143903C1 (ru) | 1993-02-19 | 2000-01-10 | Ниппон Синяку Ко., Лтд. | Фармацевтическая композиция, содержащая сополимер нуклеиновой кислоты |
US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
US5648211A (en) | 1994-04-18 | 1997-07-15 | Becton, Dickinson And Company | Strand displacement amplification using thermophilic enzymes |
EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
PT787200E (pt) | 1994-10-28 | 2005-08-31 | Univ Pennsylvania | Adenovirus melhorado e metodos para a sua utilizacao |
JP3189000B2 (ja) | 1994-12-01 | 2001-07-16 | 東ソー株式会社 | 特定核酸配列の検出方法 |
US5872154A (en) | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
US5707618A (en) | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US6019978A (en) | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
US5710029A (en) | 1995-06-07 | 1998-01-20 | Gen-Probe Incorporated | Methods for determining pre-amplification levels of a nucleic acid target sequence from post-amplification levels of product |
EP0833934B2 (en) | 1995-06-15 | 2012-08-15 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5854206A (en) | 1995-08-25 | 1998-12-29 | Corixa Corporation | Compounds and methods for treatment and diagnosis of prostate cancer |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
US6121489A (en) | 1996-03-05 | 2000-09-19 | Trega Biosciences, Inc. | Selectively N-alkylated peptidomimetic combinatorial libraries and compounds therein |
AU728186B2 (en) | 1996-03-15 | 2001-01-04 | Corixa Corporation | Compounds and methods for immunotherapy and immunodiagnosis of prostate cancer |
AU713667B2 (en) | 1996-04-12 | 1999-12-09 | Phri Properties, Inc. | Detection probes, kits and assays |
EP0929814A1 (en) * | 1996-10-07 | 1999-07-21 | Meat And Livestock Commission | Assay for duroc muscle fibre type |
US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
HUP0002095A3 (en) | 1997-02-25 | 2002-02-28 | Corixa Corp Seattle | Compounds for immunotherapy of prostate cancer and methods for their use |
US20030185830A1 (en) | 1997-02-25 | 2003-10-02 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
CA2283267A1 (en) | 1997-03-07 | 1998-09-11 | Clare Chemical Research Llc | Fluorometric detection using visible light |
US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
EP1007650B1 (en) | 1997-04-10 | 2009-03-18 | Stichting Katholieke Universiteit University Medical Centre Nijmegen | Pca3, pca3 genes, and methods of use |
US5830730A (en) | 1997-05-08 | 1998-11-03 | The Regents Of The University Of California | Enhanced adenovirus-assisted transfection composition and method |
WO1999002685A1 (en) | 1997-07-11 | 1999-01-21 | Introgene B.V. | Interleukin-3 gene therapy for cancer |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
EP1092047B1 (en) | 1998-07-02 | 2009-08-26 | Gen-Probe Incorporated | Molecular torches |
EP1109896A4 (en) | 1998-08-14 | 2005-11-02 | Aventis Pharm Prod Inc | ADENOVIRUS FORMULATIONS FOR GENE THERAPY |
HUP0200073A3 (en) | 1998-08-27 | 2003-12-29 | Aventis Pharma Sa | Targeted adenovirus vectors for delivery of heterologous genes |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
US6828429B1 (en) | 1999-03-26 | 2004-12-07 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer |
US6303305B1 (en) | 1999-03-30 | 2001-10-16 | Roche Diagnostics, Gmbh | Method for quantification of an analyte |
DE60014762T2 (de) | 1999-05-24 | 2005-10-13 | Tosoh Corp., Shinnanyo | Methode zum Nachweis von Ribonukleinsäuren |
JP2004504068A (ja) * | 2000-07-27 | 2004-02-12 | ザ オーストラリアン ナショナル ユニバーシティー | コンビナトリアル・プローブ及びそのための用途 |
US6537811B1 (en) * | 2001-08-01 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of SAP-1 expression |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
ATE309393T1 (de) | 2001-09-06 | 2005-11-15 | Adnagen Ag | Verfahren zum qualitativen und/oder quantitativen nachweis von zellen |
WO2003070966A2 (en) | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc | RNA INTERFERENCE MEDIATED TARGET DISCOVERY AND TARGET VALIDATION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
JP2006525027A (ja) | 2003-05-01 | 2006-11-09 | ジェン−プロウブ インコーポレイテッド | 分子スイッチを含むオリゴヌクレオチド |
US7834163B2 (en) * | 2003-06-26 | 2010-11-16 | Exonhit Therapeutics S.A. | Prostate specific genes and the use thereof as targets for prostate cancer therapy |
WO2005038054A1 (en) | 2003-10-20 | 2005-04-28 | Zicai Liang | METHOD OF MEASURING THE EFFICACY OF siRNA MOLECULES |
GB0327726D0 (en) | 2003-11-28 | 2003-12-31 | Isis Innovation | Method |
DE602005026730D1 (de) | 2004-08-27 | 2011-04-14 | Gen Probe Inc | Einfach-Primernukleinsäuren-Erweiterungsverfahren |
US9957569B2 (en) * | 2005-09-12 | 2018-05-01 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
-
2010
- 2010-01-08 BR BRPI1004572A patent/BRPI1004572A2/pt not_active IP Right Cessation
- 2010-01-08 US US13/145,067 patent/US20120015839A1/en not_active Abandoned
- 2010-01-08 AU AU2010203517A patent/AU2010203517B2/en not_active Ceased
- 2010-01-08 WO PCT/US2010/020501 patent/WO2010081001A2/en active Application Filing
- 2010-01-08 KR KR1020117018449A patent/KR20110111474A/ko not_active Application Discontinuation
- 2010-01-08 CN CN2010800108622A patent/CN102639709A/zh active Pending
- 2010-01-08 JP JP2011545455A patent/JP2012514475A/ja active Pending
- 2010-01-08 EP EP10703540A patent/EP2382328A2/en not_active Withdrawn
- 2010-01-08 CA CA2749113A patent/CA2749113A1/en not_active Abandoned
-
2011
- 2011-07-04 IL IL213916A patent/IL213916A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20110111474A (ko) | 2011-10-11 |
AU2010203517B2 (en) | 2012-08-16 |
WO2010081001A2 (en) | 2010-07-15 |
AU2010203517A1 (en) | 2011-08-11 |
JP2012514475A (ja) | 2012-06-28 |
CA2749113A1 (en) | 2010-07-15 |
US20120015839A1 (en) | 2012-01-19 |
CN102639709A (zh) | 2012-08-15 |
EP2382328A2 (en) | 2011-11-02 |
IL213916A0 (en) | 2011-07-31 |
WO2010081001A3 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1004572A2 (pt) | "fusões genéticas recorrentes em câncer | |
IL212964A0 (en) | Recurrent gene fusions in prostate cancer | |
DOP2011000288A (es) | Fusiones y conjugados de farmaco | |
ZA201000128B (en) | Recurrent gene fusions in prostate cancer | |
EP2478120A4 (en) | REZIDIVATING GENEFUSIONS IN PROSTATE CANCER | |
EP2225667A4 (en) | REAL TIME COMMENTARY UNIT | |
BR112012012872A2 (pt) | "pirrolindinas de espiroindolinona" | |
EP2257885A4 (en) | LOCATION INFORMATION IN PRESENCE | |
BRPI0914544A2 (pt) | derivados de pirimidona substituídos | |
DK2154967T3 (da) | Pyrimidinderivater | |
DK2132326T3 (da) | Fremgangsmåder | |
BRPI0811115A2 (pt) | Compostos de heteroarilamida pirimidona | |
GB2452092B (en) | Improvements in or relating to amphibians | |
PL2176664T3 (pl) | Ccr4 jako marker nowotworowy | |
HK1214177A1 (zh) | 用於癌症的肽治療劑 | |
BRPI0807004A2 (pt) | Sal | |
DE112008003753B8 (de) | Reißverschluss | |
BRPI1008173A2 (pt) | "derivados de piridina espiroindolinona" | |
BRPI0811094A2 (pt) | Derivados de heteroarilamida pirimidona | |
DK2396659T3 (da) | RBM3-protein i testikelkræftdiagnostik og -prognostik | |
DE112010000285A5 (de) | Neue permanente humane zelllinie | |
BR112012005344A2 (pt) | "combustível avançado de fusão" | |
FI20096190A0 (fi) | Tutkimuslaite | |
GB2454206B (en) | Improvements in & relating to construction | |
DK2107178T3 (da) | Tagkonstruktion med todimensionel hvælving |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |